Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 0 · 0%

Pegloticase every two weeks (biweekly) vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 5.45 [1.38, 21.54]
1 study · 79 participants
Moderate

Pegloticase every two weeks (biweekly) vs placebo

Joint pain reduction ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Quality of life ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Serum urate normalisation ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Function ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 7.59 [1.04, 55.55]
1 study · 128 participants
Moderate

Pegloticase every two weeks (biweekly) vs placebo

Total adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 0.99 [0.91, 1.07]
1 study · 128 participants
Moderate